Clinical trials in allogeneic blood and marrow transplantation (alloBMT) are often developed from observations made using preclinical models. My research focus at the University of Wisconsin has been on using mouse models of alloBMT to optimize therapies that prevent graft-versus-host-disease (GVHD) and maximize graft-versus-tumor (GVT) effects. My background has been in testing tumor vaccine-based strategies using combinations of murine donor and recipients to elicit subclinical or lethal GVHD. My main focus has been on understanding the biology of delayed infusions of T cells, how they cause GVHD pathology and their interactions with antigen presenting cells generated from the donor graft. My present research is investigating the role of JAK1/STAT1 signaling on plasmacytoid dendritic cells in preventing GVHD and preserving GVT effects after alloBMT. In addition, we are developing strategies to monitor lymphocyte trafficking after alloBMT by magnetic resonance imaging.
Christian Capitini, MD
1111 Highland Ave
Madison, WI 53705
Using mouse models of allogeneic blood and marrow transplantation (alloBMT) to optimize therapies that prevent graft-versus-host-disease (GVHD) and maximize graft-versus-tumor (GVT) effects